

Krebs Biochemicals & Industries Limited

CIN: L24110AP1991PLC103912



Date: 08-11-2023

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.
Scrip Code : 524518

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E), Mumbai- 400051.
Scrip Code : KREBSBIO

Dear Sir / Madam,

Sub: Outcome of Board Meeting under Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015:

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the following which were taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

1. Unaudited Financial Results of the Company for the 2nd quarter and half year ended September 30, 2023.
2. Limited Review Report by the Auditors on the Unaudited Financial Results for the 2nd quarter and half year ended September 30, 2023.

The Meeting of the Board of Directors commenced at 1:00 pm and concluded at 2.30 p.m.

The above is for your information and record.

Thanking you,

Yours Faithfully

For Krebs Biochemicals and Industries Limited

Jitendra Shah
Managing Director & CEO
Email:com_sec@krebbsbiochem.com

KREBS BIOCHEMICALS & INDUSTRIES LIMITED
CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30,2023



(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2023 (Un Audited)	30.06.2023 (Un Audited)	30.09.2022 (Un Audited)	30.09.2023 (Un Audited)	30.09.2022 (Un Audited)	31.03.2023 (Audited)
1	Revenue from Operations	1,489.01	1,058.13	2,094.25	2,547.14	3,158.31	5213.44
2	Other Income	17.42	3.75	27.46	21.17	40.40	62.01
3	Total Income from operations (1+2)	1,506.43	1,061.88	2,121.71	2,568.31	3,198.71	5,275.46
4	Expenses						
	a) Cost of Material Consumed	62.79	196.63	149.58	259.42	1,194.71	1,536.24
	b)Purchase of Stock in Trade	-	-	438.64	-	438.64	444.41
	c) Changes in Inventories of Finished goods, Work-In-Progress	142.59	(160.10)	750.27	(17.51)	456.52	587.10
	d) Employee Benefits Expenses	408.89	406.38	376.32	815.27	742.50	1,584.41
	e) Finance Costs	113.41	109.73	74.21	223.14	104.64	297.32
	f) Depreciation and Amortisation Expense	171.08	165.32	169.28	336.40	338.56	655.85
	g) Other Expenses	964.79	877.21	569.55	1,842.00	1,142.94	2,639.32
	Total Expenses (4)	1,863.56	1,595.17	2,527.85	3,458.73	4,418.51	7,744.65
5	Profit / (Loss) before exceptional Items and tax (3±4)	(357.13)	(533.29)	(406.14)	(890.42)	(1,219.80)	(2,469.19)
6	Exceptional Items:						
7	Profit / (Loss) before Tax (5 ± 6)	(357.13)	(533.29)	(406.14)	(890.42)	(1,219.80)	(2,469.19)
8	Tax Expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	Profit / (Loss) for the period (7 ± 8)	(357.13)	(533.29)	(406.14)	(890.42)	(1,219.80)	(2,469.19)
10	Other Comprehensive Income (OCI)						
i	Items that will not be reclassified to profit or Loss	-	-	-	-	-	32.28
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-	-
iii	Items that will be reclassified to profit or Loss	-	-	-	-	-	-
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-	-	32.28
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-	32.28
11	Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)	(357.13)	(533.29)	(406.14)	(890.42)	(1,219.80)	(2,436.91)
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	2,156.06	2,156.06	2,156.06	2,156.06	2,156.06
13	Other Equity excluding Revaluation Reserve	-	-	-	-	-	(13,207.37)
14	Earning Per Share (of Rs.10/- each) (not Annualised)						
	a) Basic	(1.66)	(2.47)	(1.88)	(4.13)	(5.66)	(11.30)
	b) Diluted	(1.66)	(2.47)	(1.88)	(4.13)	(5.66)	(11.30)
15	Net Worth (including Retained Earnings)						(9,946.23)

See accompanying notes to the Financial results

- The above results have been reviewed by the Audit Committee at its meeting held on 8th November, 2023 and approved by the Board of Directors of the Company at its meeting held on 8th November, 2023. The results are subjected to limited review by statutory auditors.
- The Company is operating in one segment only hence no segment results have been disclosed.
- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.

Place: Mumbai
Date: 08.11.2023



Jitendra Shah

Jitendra Shah
Managing Director
DIN : 09377846

KREBS BIOCHEMICALS & INDUSTRIES LIMITED


CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031


Statement of Assets and Liabilities


Rs. In Lacs

Particulars	As at 30.09.2023 Un Audited	As at 31.03.2023 Audited
ASSETS		
Non Current Assets		
(a)Property, Plant and Equipment	15,091.78	14,646.83
(b)Capital Work in Progress	19.46	224.34
(c)Other Intangible Assets	74.80	83.99
(d)Intangible assets under development	184.71	184.71
(e)Financial Assets	243.96	237.56
(f)Other Non Current Assets	556.30	514.64
Total Non Current Assets	16,171.02	15,892.08
Current Assets		
(a)Inventories	1,114.65	1,194.56
(b)Financial Assets		
(i) Trade Receivables	96.33	52.52
(ii) Cash & Cash Equivalents	7.83	8.58
(iii) Other Financial Assets	195.94	28.59
(c)Other Current Assets	226.99	321.84
Total Current Assets	1,641.74	1,606.09
Total Assets	17,812.75	17,498.17
EQUITY AND LIABILITIES		
Equity		
(a)Equity Share Capital	2,156.06	2,156.06
(b)Other Equity	(12,992.71)	(12,102.29)
Total Equity	(10,836.65)	(9,946.23)
Liabilities		
Non Current Liabilities		
(a)Financial Liabilities		
(i)Long Term Borrowings	17,800.00	17,324.65
(ii)Other Financial Liabilities	554.18	449.67
(b)Provisions	30.66	30.66
(c)Retirement benefit obligations	228.96	228.96
(d)Other Non Current Liabilities	4,500.00	4,500.00
Total Non Current Liabilities	23,113.79	22,533.93
Current Liabilities		
(a)Financial Liabilities		
(i)Short Term Borrowings	982.06	999.04
(ii)Trade Payables		
(a) Total outstanding dues of micro and small enterprises	305.20	218.11
(b) Total outstanding dues of creditors other than micro and small enterprises	1,363.15	1,309.95
(iii)Other Financial Liabilities	1,221.17	1,027.87
(b)Other Current Liabilities	1,489.23	1,229.29
(c)Provisions	117.22	74.67
(d)Retirement benefit obligations	57.61	51.54
Total Current Liabilities	5,535.63	4,910.47
Total Equity and Liabilities	17,812.75	17,498.17



Place: Mumbai
Date: 08.11.2023


Jitendra Shah
Managing Director
DIN : 09377846



KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912


Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031


Cash Flow Statement for the Half Year Ended 30.09.2023


(Rs. In Lacs)

Particulars	Half Year Ended 30.09.2023	Half Year Ended 30.09.2022
Cash Flow from Operating Activities		
Net Profit before tax and exceptional items	(890.42)	(1,219.81)
Adjustments for:		
Depreciation and Amortisation Expenses	336.40	338.56
Non Current provisions		9.48
Financial Charges	223.14	104.64
Operating Profit before Working Capital Changes	(330.88)	(767.13)
Changes in Working Capital		
(Increase)/Decrease in Inventories	79.91	1,137.39
(Increase)/Decrease in Trade Receivables	(43.81)	59.95
(Increase)/Decrease in Other Financial Assets	(167.35)	(399.03)
(Increase)/Decrease in Other Current Assets	94.85	291.99
(Increase)/Decrease in Financial Assets	(6.40)	(12.78)
(Increase)/Decrease in Other Non Current Assets	(41.66)	(10.00)
Increase/(Decrease) in Retirement benefit obligations	6.07	(38.32)
Increase/(Decrease) in Current Provisions	42.55	1.21
Increase/(Decrease) in Trade Payables	140.29	(2,148.64)
Increase/(Decrease) in Other financial liabilities	193.30	(52.72)
Increase/(Decrease) in financial liabilities	(16.98)	(53.15)
Increase/(Decrease) in Other Current Liabilities	259.94	(92.57)
Cash generated from Operations	540.70	(1,316.67)
Net Cash Flow from Operating Activities	209.83	(2,083.79)
(Increase)/Decrease of Property, Plant & Equipment		
Proceeds from / (Payment to) Capital Work-in-Progress	204.88	(719.69)
Proceeds from / (Payment to) Property, Plant & Equipment	(772.17)	-
Proceeds from / (Payment to) Other Financial Liabilities	104.51	(224.86)
Cash Flow from Investing Activities	(462.78)	(944.55)
Financial Charges	(223.14)	(104.64)
Proceeds from / (Payment to) borrowings	475.35	3,131.65
Proceeds from / (Payment to) Share Capital	-	-
Cash Flow from Financing Activities	252.21	3,027.01
Net Increase (Decrease) in Cash and Cash equivalents	(0.75)	(1.32)
Cash and Cash equivalents as at the beginning of the year	8.58	10.06
Cash and Cash equivalents at the end of the year	7.83	8.74

Place: Mumbai
Date: 08.11.2023




 Jitendra Shah,
 Managing Director
 DIN : 09377846







INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
KREBS BIOCHEMICALS AND INDUSTRIES LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of KREBS BIOCHEMICALS ANDI INDUSTRIES LIMITED ("the Company"), for the quarter ended September 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BHAVANI & CO
Chartered Accountants
(Firm's Registration No. 012139S)




CA. S. KAVITHA PADMINI
Partner
(Membership No. 229966)
UDIN: 23229966BGXVWG5024

Place : Mumbai
Date : 08-11-2023